FindTrial
Sign In

Cineraria maritima eye drops in the prevention of progression of immature cataract

Anti-cataract Effects Of Cineraria maritima Eye Drops In The Progression Of Immature Cataract: A Pilot Open-label Prospective Observational Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/097273
Enrollment
72
Registered
2025-11-12
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H269- Unspecified cataract

Interventions

Intervention1: Cineraria maritima eye drops (without alcohol): Cineraria maritima eye drops (without alcohol), in compliance with pharmacopoeial standards procured from GMP compliant pharmaceutical fi

Sponsors

Central Council for Research in Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients between 40 to 80 years of age Gender: both Visual acuity better than or equal to 6/60 Snellen’s chart Patients who meet the diagnostic standards of immature cataract using slit lamp Biomicroscopic examination.

Exclusion criteria

Exclusion criteria: Patients suffering from congenital Cataract, mature and hypermature Cataract, Glaucoma, Diabetic Retinopathy, Hypertensive retinopathy, Macular degeneration, Retinitis pigmentosa Patients with uncontrolled blood sugar and blood pressure Patients who are under steroid treatment or Immunosuppressive therapy or any cataract-inducing medications Unwilling to participate in the study

Design outcomes

Primary

MeasureTime frame
1. Change in symptoms & signs– blurring of vision,visualization of non-existing things, nyctalopia, hemeralopia, glare, intra-ocular pressure, unaided distant visual acuity, pin hole vision, best corrected distant visual acuity using grading pattern by Snellen’s chart and Jaeger’s chart reading 2. Change in grading of cataractous lens, according to lenticular opacity classification system III to assess changes in the area and density of lenticular opacity by slit lamp biomicroscopic examination, in tangentional sectioning and retro illumination techniqueTimepoint: 1. Baseline, end of 3rd month, 6th month, 9th month, 12th month, 15th month & 18th month 2. Baseline, end of 6th month, 12th month & 18th month—

Secondary

MeasureTime frame
Change in visual score & quality of life to be assessed by VFQ-25Timepoint: baseline, end of 3rd month, 6th month, 9th month, 12th month, 15th month & 18th month—

Countries

India

Contacts

Public ContactDr Divya Taneja

Central Council for Research in Homoeopathy

renumittal8@gmail.com9717511115

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026